Saswati N Chand
Overview
Explore the profile of Saswati N Chand including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
509
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sardar S, McNair C, Ravindranath L, Chand S, Yuan W, Bogdan D, et al.
Oncogene
. 2024 Sep;
43(43):3197-3213.
PMID: 39266679
Castration resistant prostate cancer (CRPC) remains an incurable disease stage with ineffective treatments options. Here, the androgen receptor (AR) coactivators CBP/p300, which are histone acetyltransferases, were identified as critical mediators...
2.
Sardar S, McNair C, Ravindranath L, Chand S, Yuan W, Bogdan D, et al.
bioRxiv
. 2024 May;
PMID: 38766099
Castration resistant prostate cancer (CRPC) remains an incurable disease stage with ineffective treatments options. Here, the androgen receptor (AR) coactivators CBP/p300, which are histone acetyltransferases, were identified as critical mediators...
3.
Mandigo A, Yuan W, Xu K, Gallagher P, Pang A, Guan Y, et al.
Cancer Discov
. 2021 Apr;
11(9):2334-2353.
PMID: 33879449
Loss of the retinoblastoma (RB) tumor suppressor protein is a critical step in reprogramming biological networks that drive cancer progression, although mechanistic insight has been largely limited to the impact...
4.
The circadian cryptochrome, CRY1, is a pro-tumorigenic factor that rhythmically modulates DNA repair
Shafi A, McNair C, McCann J, Alshalalfa M, Shostak A, Severson T, et al.
Nat Commun
. 2021 Jan;
12(1):401.
PMID: 33452241
Mechanisms regulating DNA repair processes remain incompletely defined. Here, the circadian factor CRY1, an evolutionally conserved transcriptional coregulator, is identified as a tumor specific regulator of DNA repair. Key findings...
5.
Welti J, Sharp A, Brooks N, Yuan W, McNair C, Chand S, et al.
Cancer Discov
. 2021 Jan;
11(5):1118-1137.
PMID: 33431496
Resistance to androgen receptor (AR) blockade in castration-resistant prostate cancer (CRPC) is associated with sustained AR signaling, including through alternative splicing of AR (AR-SV). Inhibitors of transcriptional coactivators that regulate...
6.
Jain A, Agostini L, McCarthy G, Chand S, Ramirez A, Nevler A, et al.
Cancer Res
. 2019 Jul;
79(17):4491-4502.
PMID: 31273064
Patients with metastatic pancreatic ductal adenocarcinoma (PDAC) have an average survival of less than 1 year, underscoring the importance of evaluating novel targets with matched targeted agents. We recently identified...
7.
Dylgjeri E, McNair C, Goodwin J, Raymon H, McCue P, Shafi A, et al.
Clin Cancer Res
. 2019 Jul;
25(18):5623-5637.
PMID: 31266833
Purpose: DNA-dependent protein kinase catalytic subunit (DNA-PK) is a pleiotropic kinase involved in DNA repair and transcriptional regulation. DNA-PK is deregulated in selected cancer types and is strongly associated with...
8.
Schiewer M, Mandigo A, Gordon N, Huang F, Gaur S, de Leeuw R, et al.
EMBO Mol Med
. 2018 Nov;
10(12).
PMID: 30467127
PARP-1 holds major functions on chromatin, DNA damage repair and transcriptional regulation, both of which are relevant in the context of cancer. Here, unbiased transcriptional profiling revealed the downstream transcriptional...
9.
Pan H, Strickland A, Madhu V, Johnson Z, Chand S, Brody J, et al.
Matrix Biol
. 2018 Aug;
77:23-40.
PMID: 30092282
Nucleus pulposus (NP) cells reside in the hypoxic niche of the intervertebral disc. Studies have demonstrated that RNA-binding protein HuR modulates hypoxic signaling in several cancers, however, its function in...
10.
Chand S, Zarei M, Schiewer M, Kamath A, Romeo C, Lal S, et al.
Cancer Res
. 2017 Jul;
77(18):5011-5025.
PMID: 28687616
The majority of pancreatic ductal adenocarcinomas (PDAC) rely on the mRNA stability factor HuR (ELAV-L1) to drive cancer growth and progression. Here, we show that CRISPR-Cas9-mediated silencing of the HuR...